Published in J Viral Hepat on November 01, 2013
Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection (Care2Cure) | NCT02707991
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program. J Gen Intern Med (2015) 0.90
The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat (2016) 0.89
Public health clinic-based hepatitis C testing and linkage to care in baltimore. J Viral Hepat (2016) 0.86
Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol (2016) 0.85
Cancers attributable to infections among adults with HIV in the United States. AIDS (2015) 0.82
Activins and Follistatin in Chronic Hepatitis C and Its Treatment with Pegylated-Interferon-α Based Therapy. Mediators Inflamm (2015) 0.82
Lack of health insurance limits the benefits of hepatitis C virus screening: insights from the National Health and Nutrition Examination Hepatitis C follow-up study. Am J Gastroenterol (2015) 0.82
Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality. BMC Gastroenterol (2014) 0.81
The undiagnosed chronically-infected HCV population in France. Implications for expanded testing recommendations in 2014. PLoS One (2015) 0.80
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open (2015) 0.80
"Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment. Drug Alcohol Depend (2015) 0.77
Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ (2014) 0.77
Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin. Int J Clin Exp Med (2015) 0.76
Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy. J Prim Care Community Health (2014) 0.76
For patients with rheumatic disease and hepatitis C infection: the end of interferon. RMD Open (2015) 0.76
Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States. J Clin Transl Hepatol (2016) 0.76
Hepatitis C virus reinfection after liver transplant: New chances and new challenges in the era of direct-acting antiviral agents. World J Hepatol (2015) 0.76
Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama. Clin Infect Dis (2015) 0.76
Hepatitis C virus: A time for decisions. Who should be treated and when? World J Gastrointest Pharmacol Ther (2016) 0.76
Imaging Based Methods of Liver Fibrosis Assessment in Viral Hepatitis: A Practical Approach. Interdiscip Perspect Infect Dis (2015) 0.75
Characterizing Failure to Establish Hepatitis C Care of Baby Boomers Diagnosed in the Emergency Department. Open Forum Infect Dis (2016) 0.75
Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy. J Clin Transl Hepatol (2016) 0.75
Engagement in the Hepatitis C Care Cascade Among Homeless Veterans, 2015. Public Health Rep (2017) 0.75
The effects of pegylated interferon-α and ribavirin on liver and serum concentrations of activin-A and follistatin in normal Wistar rat: a preliminary report. BMC Res Notes (2015) 0.75
HCV Council - critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int (2015) 0.75
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. Antimicrob Agents Chemother (2014) 0.75
Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C. Isr J Health Policy Res (2017) 0.75
Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target? Front Pharmacol (2017) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med (2006) 18.63
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep (1998) 12.78
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med (2012) 7.56
Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep (2012) 6.91
Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med (2011) 6.69
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2011) 6.63
Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med (2012) 6.44
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med (2013) 6.08
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Projecting future complications of chronic hepatitis C in the United States. Liver Transpl (2003) 3.84
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med (2011) 3.80
Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2013) 3.65
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med (2013) 3.39
Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology (2011) 3.38
Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology (2010) 3.22
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis (2013) 3.17
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med (2013) 2.68
Hepatitis C in the United States. N Engl J Med (2013) 2.63
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol (2010) 2.57
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology (2011) 2.54
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol (2010) 2.50
Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med (2013) 2.46
Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology (2010) 2.30
Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med (2013) 2.25
Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009. MMWR Morb Mortal Wkly Rep (2011) 2.18
Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol (2003) 2.18
American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology (2006) 2.14
Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep (2013) 2.11
Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med (2005) 1.97
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci (2007) 1.83
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology (2013) 1.78
Management of hepatitis C patients by primary care physicians in the USA: results of a national survey. J Viral Hepat (2001) 1.70
Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat (2009) 1.69
Non-invasive markers for hepatic fibrosis. BMC Gastroenterol (2011) 1.65
Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology (2007) 1.55
HCV screening practices and prevalence in an MCO, 2000-2007. Am J Manag Care (2011) 1.51
All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm (2011) 1.44
Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis (2002) 1.42
Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med (2004) 1.41
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis (2013) 1.38
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust (2012) 1.33
Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol (2012) 1.32
Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat (2010) 1.31
Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med (2004) 1.24
The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend (2005) 1.23
Rates and predictors of hepatitis C virus treatment in HCV-HIV-coinfected subjects. Aliment Pharmacol Ther (2006) 1.23
Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis (2013) 1.23
Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr (2004) 1.21
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis (2012) 1.20
Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat (2011) 1.19
Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol (2010) 1.17
Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis (2011) 1.16
Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat (2011) 1.15
Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy (2007) 1.15
Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Dig Liver Dis (2012) 1.14
Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. Clin Infect Dis (2013) 1.13
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One (2008) 1.13
Outcomes of a Hepatitis C screening program at a large urban VA medical center. J Clin Gastroenterol (2008) 1.10
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study. Clin Infect Dis (2013) 1.09
Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther (2012) 1.09
The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat (2005) 1.08
The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology (2013) 1.08
Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS (2004) 1.06
Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend (2006) 1.05
Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat (2010) 1.05
Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother (2010) 1.05
A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. Am J Gastroenterol (2011) 1.03
Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis (2013) 1.00
Managing chronic hepatitis C acquired through intravenous drug use. QJM (2001) 0.99
Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc (2012) 0.99
Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat (2010) 0.99
Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. J Clin Virol (2012) 0.98
Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med (2010) 0.97
Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol (2006) 0.95
Biopsy no more; changing the screening and diagnostic algorithm for hepatitis C. Clin Gastroenterol Hepatol (2012) 0.94
A systematic review of provider knowledge of hepatitis C: is it enough for a complex disease? Dig Dis Sci (2007) 0.93
Expanded hepatitis C virus screening recommendations promote opportunities for care and cure. Ann Intern Med (2013) 0.92
Factors to improve the management of hepatitis C in drug users: an observational study in an addiction centre. Gastroenterol Res Pract (2010) 0.88
High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol (2005) 0.83
Antiviral activity of telaprevir and boceprevir for the treatment of hepatitis C virus infection in treatment-experienced patients. Clin Res Hepatol Gastroenterol (2011) 0.78
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Control Clin Trials (1985) 6.22
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Breaking the camel's back: multicenter clinical trials and local institutional review boards. Ann Intern Med (2001) 5.76
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology (1999) 5.55
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med (2000) 4.83
Glanders in a military research microbiologist. N Engl J Med (2001) 4.77
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med (1989) 4.69
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV infection is blocked in vitro by recombinant soluble CD4. Nature (1988) 4.58
The role of psychological and biological factors in postinfective gut dysfunction. Gut (1999) 4.54
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 4.45
CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med (1993) 4.43
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology (1999) 4.11
Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther (2014) 3.91
Trends in perinatal transmission of HIV/AIDS in the United States. JAMA (1999) 3.86
Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health (2000) 3.82
Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.68
Liver fibrosis in overweight patients. Gastroenterology (2000) 3.56
National HIV case reporting for the United States. A defining moment in the history of the epidemic. N Engl J Med (1997) 3.52
The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology (2010) 3.36
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science (1988) 3.12
Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ (2000) 3.10
The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E. Genes Dev (1993) 3.10
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998. Thorax (2001) 3.01
HIV infection among patients in U.S. acute care hospitals. Strategies for the counseling and testing of the hospital patients. The Hospital HIV Surveillance Group. N Engl J Med (1992) 3.01
Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis (2000) 3.01
Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab (1999) 2.98
The completeness, validity, and timeliness of AIDS surveillance data. Ann Epidemiol (2001) 2.89
Genomic imprinting and the strange case of the insulin-like growth factor II receptor. Cell (1991) 2.80
Peptic ulcer bleeding in patients with or without cirrhosis: different diseases but the same prognosis? Aliment Pharmacol Ther (2012) 2.68
BLAST-2 [EBVCS], an early cell surface marker of human B cell activation, is superinduced by Epstein Barr virus. J Immunol (1985) 2.66
A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet (1993) 2.64
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
Prediction of in-hospital mortality and length of stay using an early warning scoring system: clinical audit. Clin Med (2006) 2.63
Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol (1997) 2.55
Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science (1987) 2.51
Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med (1996) 2.50
Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother (1987) 2.47
Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis (2001) 2.47
Detection of human anti-HTLV-III antibodies by indirect immunofluorescence using fixed cells. Transfusion (1985) 2.45
Mass mortality of harbor seals: pneumonia associated with influenza A virus. Science (1982) 2.45
Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology (2009) 2.41
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology (1999) 2.36
Endoscopic transhiatal drainage of a mediastinal pancreatic pseudocyst. Endoscopy (2004) 2.34
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat (2011) 2.30
Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology (2001) 2.29
Detection by immune electron microscopy of the Snow Mountain agent of acute viral gastroenteritis. J Infect Dis (1982) 2.26
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat (2007) 2.19
Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Aliment Pharmacol Ther (2014) 2.18
Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology (1999) 2.18
HIV testing patterns: where, why, and when were persons with AIDS tested for HIV? AIDS (1995) 2.12
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology (1999) 2.11
Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax (2005) 2.09
Incidence of retinopathy of prematurity in Lothian, Scotland, from 1990 to 2004. Arch Dis Child Fetal Neonatal Ed (2008) 2.08
Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med (1994) 2.05
Hepatitis E: an emerging infectious disease. Epidemiol Rev (1999) 2.04
Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med (1985) 1.99
A comparison of the I-gel supraglottic airway as a conduit for tracheal intubation with the intubating laryngeal mask airway: a manikin study. Resuscitation (2009) 1.99
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol (1999) 1.98
Severe exacerbation of undiagnosed restless legs syndrome presenting as a movement disorder emergency. Eur J Neurol (2013) 1.97
Isolation of HTLV-III/LAV from cervical secretions of women at risk for AIDS. Lancet (1986) 1.96
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Autoantibodies to the extracellular domain of the calcium sensing receptor in patients with acquired hypoparathyroidism. J Clin Invest (1996) 1.88
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis (2000) 1.87
Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat (2007) 1.86
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA (1989) 1.84
Treatment of cytomegalovirus retinitis with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine. Ann Intern Med (1985) 1.83
Mechanism of cellulose synthesis in Agrobacterium tumefaciens. J Bacteriol (1995) 1.80
Chronic viral hepatitis and the human genome. Hepatology (2000) 1.79
Infrequency of isolation of HTLV-III virus from saliva in AIDS. N Engl J Med (1985) 1.78
Programming placental nutrient transport capacity. J Physiol (2006) 1.78
Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum (1999) 1.77
Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. N Engl J Med (1993) 1.77
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76